Skip to content

Margaret Haney

4 papers in the library · publishing 2007-2023

Papers

Sort Most recent Most cited

Value Signals Guiding Choices for Cannabis Versus Non-Drug Rewards in Regular Cannabis Users

March 15, 2023 Will Lawn, Xuejun Hao, Anna B. Konova et al. preprint

Background: Despite the critical role of choice processes in substance use disorders, the neurobehavioral mechanisms guiding human decisions about drugs remain poorly understood. We adapted a neuroeconomic framework to characterize the neural encoding of subjective value (SV) for cannabis versus non-drug rewards (snacks) in near-daily cannabis users. We also assessed the impact of cannabis and...

Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.

Depression and Anxiety August 1, 2020 Reilly R Kayser, Margaret Haney, Marissa Raskin et al.

Preclinical data implicate the endocannabinoid system in the pathology underlying obsessive-compulsive disorder (OCD), while survey data have linked OCD symptoms to increased cannabis use. Cannabis products are increasingly marketed as treatments for anxiety and other OCD-related symptoms. Yet, few studies have tested the acute effects of cannabis on psychiatric symptoms in humans. We recruited...

Opioid antagonism enhances marijuana's effects in heavy marijuana smokers.

Psychopharmacology August 2010 Ziva D Cooper, Margaret Haney

Studies in laboratory animals strongly suggest reciprocal modulation of the opioidergic and endocannabinoid systems, a relationship that has not been demonstrated in humans. This study sought to clarify this interaction by assessing how a range of naltrexone doses altered the subjective, cognitive, and cardiovascular effects of marijuana. Daily marijuana smokers (n = 29) participated in this...

Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology June 2007 Margaret Haney

In non-human animals, opioid antagonists block the reinforcing and discriminative-stimulus effects of Delta(9)-tetrahydrocannabinol (THC), while in human marijuana smokers, naltrexone (50 mg) enhances the reinforcing and subjective effects of THC. The objective of this study was to test a lower, more opioid-selective dose of naltrexone (12 mg) in combination with THC. The influence of...